On July 6, RemeGen rose 4.27% in regular trading, trading at HK$91.4/share, with turnover of HK$215 million. The rally was driven by continued innovative drug payment reform catalysts combined with restricted selling pressure from recently unlocked shares.
On July 1, approximately 193 million restricted shares (34.16% of total equity) were officially released from lock-up. However, because the company's cash dividends did not meet regulatory requirements under Shanghai Stock Exchange listing rules, unlocked shareholders are prohibited from reducing A-share holdings via centralized bidding or block trading, rendering actual selling pressure far below market expectations.
On the policy front, innovative drug payment reform continues to catalyze the sector, with medical insurance and commercial insurance dual-directory negotiations entering a substantive phase. A total of 557 drugs passed the basic medical insurance directory preliminary review, while 54 passed the commercial insurance innovative drug directory review, alongside an 8-year price protection mechanism, further expanding commercialization potential for innovative drugs.
Within the Biotechnology sector, peers showed broad strength: Innovent Bio up 3.3%, 3SBio up 2.51%, SKB Bio up 1.4%, Akeso up 1.27%, BeiGene up 0.49%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments